gist and end-of-life specialist at the Mayo Clinic in Rochester, Minn., agreed: "The reality of it is, a prescription you don't take because you can't afford to has a zero response rate. If an aromatase inhibitor costs a patient $300 out of pocket versus $70 for tamoxifen, it is important for an oncologist to know if this expense will affect the patient's compliance," he said.
Moynihan is also concerned about prescribing a high-cost treatment without fully describing its risks and benefi ts to a patient near the end of life. "If someone is going to get a very expensive therapy, their doctor needs to explain that it may only change their outcome by 6 weeks, they may have to N E W S mortgage the farm to pay for it, they will die anyway, and it may prevent them from leaving the farm to their children as a legacy. If you don't have this conversation, patients can't have a choice. You can literally break a family," Moynihan said.
Barriers to Discussion
So why aren't these conversations happening right now? Despite widespread agreement on their potential usefulness, experts said that many barriers exist.
One of the major issues is time. Most oncologists have tightly scheduled clinic appointments and no extra time to discuss the cost of care, according to all the physicians interviewed for this article.
A second roadblock is the current reimbursement system, which provides payment only for the medical care provided. "A fair question is how can we remodel the system to assure that key issues such as a discussion of a patient's insurance and personal economic issues are included among the topics covered in the course of patient's visit," Schnipper said.
Third, even if time and reimbursement were not problems, such discussions have inherent difficulty. According to ASCO, only 37% of oncologists surveyed said they were comfortable discussing costs of cancer treatment with patients. And even fewer are trained to conduct this type of conversation. "Most doctors are uncomfortable discussing the topic and may not have ready answers," said Thomas J. Smith, M.D., director of palliative care at Virginia Commonwealth University -Massey Cancer Center in Richmond.
The task force also recommended that patients initiate discussions of costs, and ASCO has created a guide for patients to facilitate these discussions. But this scenario presumes that patients want to have that conversation with their oncologists, and that is not always the case, according to some experts.
Research led by Deborah Schrag, M.D., an oncologist at the Dana -Farber Cancer Institute in Boston and a member of the ASCO task force, found that 90% of patients with advanced colorectal cancer starting chemotherapy reported that they almost never discussed the costs of prescription drugs with their doctors. Their study, presented at the May 2009 ASCO meeting, showed that even when participants were worried about drug affordability, only 12% of patients discussed these concerns with their physicians either before beginning the clinical trial or 3 months after.
"Our study corroborated what providers see in clinic," Schrag said. "When folks are in crisis and have a new diagnosis or feel immense pressure, they relegate costs to the back burner. Ninety-nine percent of patients and family members say, 'I don't care what it costs. I just want the best care for my loved one. ' " She said that once patients undergoing cancer treatment realize they are in it "for the long haul and the bills start piling up, people then turn their attention to focus on the cost aspect." Desire for the best care can present another barrier to discussion if patients fear their fi nancial problems may affect their care, said Diane Blum, executive director of CancerCare, a nonprofi t organization that assists cancer patients with fi nancial problems. "Patients are concerned that physicians might not do all the necessary treatment for an illness that will require a lot of care if cost is an issue," said Blum, another member of the ASCO task force. "And every patient wants to receive the best care."
Blum believes that doctors should take the initiative. "Physicians don't need to be fi nancial experts, but when patients are given choices for treatment, as they often are, cost should be presented to them as part of the decision they need to make, including how it might affect their patients ' ability to comply."
Health insurance may be another reason patients don't pursue discussions about costs, according to Leonard Saltz, M.D., an oncologist at Memorial Sloan -Kettering Cancer Center in New York. "Human nature is such that if I say to a patient a drug will cost $4,000 a month, he or she wants to know 'What will it cost me . . . what are my out-of-pocket costs? ' " said Saltz. "If the answer is nothing, or a small amount, he or she will most likely be happy to have such good insurance and is not going to be very concerned about the actual cost."
Saltz believes that to be relevant, a discussion of cost must be personalized to refl ect each patient's insurance coverage and immediate fi nancial concerns.
Delegating the Dialogue
Confronted with the many barriers to this kind of conversation, some larger medical centers and private practices routinely schedule patients for a meeting with a fi nancial representative to discuss costs.
At the Mayo Clinic, a fi nancial representative speaks with the patient before the fi rst visit to arrange for insurance approvals and HMO authorizations and to refer the patient for charity care or other fi nancial assistance, if needed. US Oncology, a network of private, for-profit practices that reportedly treats more than 600,000 patients every year, begins the dialogue at the fi rst visit. After the patient sees an oncologist to discuss the treatment plan, he or she meets with a fi nancial service representative to review the plan's costs, what their insurance will pay, and what they will owe out of pocket. To monitor any change in treatment or fi nancial issues, a representative speaks with the patient every 30 days to discuss potential problems, said Roy Beveridge, M.D., medical director of US Oncology and a medical oncologist at Fairfax Northern Virginia Hematology -Oncology.
In smaller community practices, it is impossible to generalize whether or how such communication takes place. But the lack of time and reimbursement for discussions of cost negatively affects practices with just a few oncologists. "Some small practices are in danger and some are going "The reality of it is, a prescription you don't take because you can't afford to has a zero response rate."
"The challenge that we have in holding down spending is there is no reasonable structure for inserting price into the patient -doctor relationship," said Bach. "Putting spending decisions either on the patient or on the doctor gives the task to a party that is totally unequipped. The problem isn't that drugs like Tarceva are expensive but that doctors are giving them to patients without a specifi c [biomarker that predicts response], so it is unlikely to work. If there is a solution, it is to make sure that under," Schnipper said. He recommends (and ASCO supports) an approach that provides information in waiting rooms and clinics to help patients understand what resources are available and advise them on the optimal way to begin a discussion of costs.
The Bigger Picture
In addition to urging dialogue on costs between oncologists and patients, the ASCO task force emphasized the need to "address the underlying factors contributing to the increasing cost of cancer care." Some experts believe that these factors are what matter most.
Peter B. Bach, M.D., a physician at Memorial Sloan -Kettering, emphasized the potential role for evidence-based medicine. A major driver of cost, he said, is patients ' insistence on, and oncologists ' prescribing, expensive therapeutics and imaging that may have little or no evidence of benefi t.
patients receive treatments that are evidence-based and valuable." Saltz, another Sloan -Kettering physician who speaks often about the cost of drugs, points to the current insurance system as one of the major underlying factors. "Health care has spun out of control due to programs like Medicaid and Medicare and third-party payers that pay six-fi gure prices for treatments that provide only incremental advantages but are priced like a cure," he said. "We have taken what economists call the 'moral hazard ' out of health care, because so many patients no longer need to make an economic decision when it comes to their treatment -to consider, 'If I buy this, what do I have to give up? ' " Saltz said that "two separate and directly antithetical issues" need to be addressedwhat society pays for health care and what individuals pay. "The only realistic way to lower the former is to increase the latter," he said, "yet to lower or eliminate the latter will necessarily increase the former."
